close

Tatva Chintan Pharma Chem Ltd

Know More
NSEBSE

1585.10-0.45 (-0.03%)

12:49 PM,27th Sep 2023

1582.05-8.95 (-0.56%)

01:04 PM,27th Sep 2023

BSE : 543321

NSE : TATVA

Sector : Industrials

ISIN Code : INE0GK401011

  • NSE
  • BSE
  • 1D
  • 5D
  • 1M
  • 6M
  • 1Y
  • 2Y
  • 5Y
  • MAX

Last Updated: Sep 27 2023 | 01:04 PM IST

Market Cap (₹ Cr)

3707

Turnover (₹ Cr)

0.17

Volume (Shares)

10615

Face Value

10

52-WK High

2624.20

52-WK High Date

29 Sep 2022

52-WK Low

1581.75

52-WK Low Date

26 Sep 2023

All Time High

2977.80

All Time High Date

03 Nov 2021

All Time Low

1581.75

All Time Low Date

26 Sep 2023

Tatva Chintan Pharma Chem Ltd

The Company was formerly incorporated as Tatva Chintan Pharma Chem Private Limited in India on 12 June 1996 under the Companies Act 2013. The status of the Company got converted from Private Limited into a Public Limited Company effective from 27 January 2021 and consequently the name of Company also changed from 'Tatva Chintan Pharma Chem Private Limited' to 'Tatva Chintan Pharma Chem Limited'. The Company is promoted by Mr. Chintan Nitin Kumar Shah Mr. Ajay Kumar Mansukhlal Patel and Mr. Shekhar Rasiklal Somani. The Company is primarily engaged in manufacturing and selling of specialty chemicals Pharma & Agro intermediates and Quaternary Ammonium Compounds (Quats). The Company is a globally recognized specialty chemical player with several market leading products in its portfolio. Considering the wide application of products the Company supply products to leading global companies across diverse industries like automotive petroleum pharmaceutical agrochemicals paints and coatings dyes and pigments personal care and flavor and fragrances with over 1300 customers. Apart from customers in India the Company export products across the globe including USA China Germany Japan South Africa and UK. The Company operate through two world class manufacturing facilities located at Dahej and Ankleshwar in Gujarat both of which are strategically located very close to the Hazira Port. These units provide the Company cost and logistics advantage and enabling seamless export and import operations. The Company's manufacturing facilities obtained ISO 9001:2015 and 14001:2015 certification for robust quality management systems. Employing modern equipment like reactors assembly lines ANFDs centrifuges and RCVDs enabled the Company to undertake multiple chemistry process. The Company successfully established an integrated model comprising world class manufacturing infrastructure complex & chemical processes warehousing facilities and technically sound R&D capabilities which enables to achieve high operational efficiency and quality to innovate & customize and to ensure sustainable operations with wide offerings. The Company has sophisticated quality control lab equipped with modern analytical equipment enabling it to detect impurities upto PPM levels and achieve `ultra-pure'grade certification. The Company Promoters identified an opportunity in manufacturing Phase Transfer Catalyst (PTC) which is a niche segment within the specialty chemicals space. With PTC as the base the Company have marked presence in the entire value chain including PTC Structure Directing Agents (SDA) Electrolyte Salts (ES) and Pharmaceutical and agrochemical intermediates and other specialty chemicals (PASC).The Company have a dedicated Department of Scientific and Industrial Research (DSIR) approved R&D centre at its Vadodara facility where qualified and experienced in-house R&D team focus on development of new products and improvement in current manufacturing processes. The Company is having modern systems and analytical development laboratory with state-of-the-art instrumentation.In 2004 the Company received licence from the FDA Gujarat at its Ankleshwar manufacturing plant.In 2007 the Company commenced Ankleshwar manufacturing facility and increased the expansion of manufacturing capacity.In 2011 the Company started commercial manufacturing of Structure Directing Agents (SDA).In 2015 the Company was accredited Appreciation Certificate for the Ankleshwar Plant from the Office of the Chief Commission of Central Excise Customs & Service Tax Vadodara Zone for its contribution to revenue and voluntary compliance with tax laws. The Company achieved revenue of nearly Rs 1 bn. The Company established a warehousing plant in The Netherlands. Tatva Chintan USA Inc. was incorporated as a wholly owned Subsidiary of TCPCL.In 2016 the Company was accorded the status of a two-star export house for the Ankleshwar plant from the Directorate General of Foreign Trade (DGFT) Ministry of Commerce and Industry (MoCI) Government of India (GoI).In 2017 manufacturing plant was established in Dahej Gujarat. In 2018 the R&D facility was set up in Vadodara.Tatva Chintan Europe BV was incorporated as wholly owned Subsidiary of the Company in year 2019.In FY 2019-20 the Company's Ankleshwar unit was converted to a zero liquid effluent discharge facility. The products proved efficiency to ensure lower by-products and waste generation in chemical processes.Additionally the Company participated in the ` Together for Sustainability' initiatives whereby sustainability sourcing practices of chemical suppliers like ecological and social aspects were assessed. Under this initiative the Company involved Ecovadis to audit sustainability practices and performance the results of which were above the industry average. This created a robust initiative and focused on retaining key customers who consider sustainability an important parameter to do business. In 2020 the Company achieved another Rs 2 billion revenue.In 2021 the manufacturing capacity at Dahej facility in Gujarat increased giving rise to aggregate installed reactor manufacturing capacity of the Company from 160 KL and 10 Assembly Lines to 280 KL and 17 Assembly Lines respectively.During the year 2021 the Company had issued 12052500 Equity Shares as Bonus Shares to all the existing shareholders of the Company in the ratio of 1.5:1 vide Board Resolution dated 03 March 2021 which was passed pursuant to passing of Special Resolution by Shareholders in ExtraOrdinary General Meeting held on 27 January 2021 against existing 8035000 Equity Shares.

Tatva Chintan Pharma Chem Ltd - Key Fundamentals

PARAMETER VALUES
Market Cap (₹ Cr)

3707

EPS - TTM (₹) [S]

18.73

P/E Ratio (X) [S]

5.26

Face Value (₹) 10
Latest Dividend (%)20.00
Latest Dividend Date 08 Sep 2023
Dividend Yield (%) 0.12
Book Value Share (₹) [S]301.29
P/B Ratio (₹) [S]5.26
[*C] Consolidated [*S] Standalone

Funds Owing this Stock

Scheme Name Amount Invested ( ₹ Cr ) No Of Shares Net Asset (%)
Nippon India Tax Saver (ELSS) Fund - (G) 133.33 773774 1.06
Nippon India Tax Saver (ELSS) Fund - (IDCW) 133.33 773774 1.06
Nippon India Tax Saver (ELSS) Fund - (IDCW-A) 133.33 773774 1.06
Nippon India Tax Saver (ELSS) Fund - Dir (IDCW-A) 133.33 773774 1.06
Nippon India Tax Saver (ELSS) Fund - Dir (G) 133.33 773774 1.06
Nippon India Tax Saver (ELSS) Fund - Direct (IDCW) 133.33 773774 1.06
SBI Magnum Midcap Fund (G) 112.00 650000 0.89
SBI Magnum Midcap Fund (IDCW) 112.00 650000 0.89
SBI Magnum Midcap Fund - Direct (IDCW) 112.00 650000 0.89
SBI Magnum Midcap Fund - Direct (G) 112.00 650000 0.89

Load more

Research Reports

Date BrokerActionPrices(Rs)Report
31-01-2023Nirmal Bang Accumulate 2176

Stock Strength

Today's Low/High

1582.00

1599.00

Week Low/High

1581.75

1650.00

Month Low/High

1581.75

1772.00

Year Low/High

1581.75

2624.00

All time Low/High

1581.60

2978.00

Share Price Returns

Period BSENSE SENSEXNIFTY
1 Week-3.45%-2.96%-2.42-1.17%
1 Month-8.86%-8.92%1.662.09%
3 Month-13.02%-12.81%4.754.53%
6 Month-7.06%-4.71%14.6615.80%
1 Year-35.73%-37.02%15.4315.65%
3 Year%%76.4278.00%

Financials

Graph
Table

Bulk/ Block

ALL
NSE
BSE
ALL
BUY
SELL
DateClient NameExchangeTransactionQuantityPrice
06-09-2023AJAY MANSUKHLAL PATEL HUFBSESELL2063661642.12
06-09-2023DAKSHA DUSHYANT PATELBSEBUY1240001646.03
06-09-2023DARSHANA NITINKUMAR SHAHBSESELL2337661639.60
06-09-2023SHEKHAR RASIKLAL SOMANIBSESELL2337671647.83
27-08-2021GOLDMAN SACHS FUNDS GOLDMAN SACHS INDIA EQUITY PORTFOLIOBSEBUY923392129.70
27-08-2021GOLDMAN SACHS INDIA FUND LIMITEDBSESELL923392129.70
29-07-2021ALPHAGREP SECURITIES PRIVATE LIMITEDNSEBUY1491452329.07
29-07-2021ALPHAGREP SECURITIES PRIVATE LIMITEDNSESELL1491452328.08
29-07-2021NK SECURITIES RESEARCH PRIVATE LIMITEDNSEBUY5813082337.65
29-07-2021NK SECURITIES RESEARCH PRIVATE LIMITEDNSESELL5813082340.16

Load More

Peer Group Comparison

NamePrice(In Rs)Chg(%)Mkt Cap(Rs Cr)Sales(Rs Cr)Profit(Rs Cr)EPS(Rs)P/E(x)

Shareholding Pattern

Jun 2023
Archive
CategoryShare(%)
Promoter75.02
Financial Institutions Banks0.00
Foreign Institutional Investors4.13
Insurance Companies0.11
Mutual Funds Uti13.57
Other Institutional Investors0.17
Indian Public6.23
Others Non Institutional Investors0.77
Custodians0.00

Corporate Action

Announcement DatePurposeFromToRemarks
Data Not Found

Price History

Search for Price History

DateOpenHighLowCloseSharesTrades
Data Not Found

Load more

Company Info

Company Information

Company Sec. & Compli. Officer : Ishwar Nayi

Registered Office: No 502/17 GIDC Estate, Ankleshwar,Bharuch,Gujarat-393002 Ph: +91-75730-46951/46952

Email:cs@tatvachintan.com

URL:http://www.tatvachintan.com